title: Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.
abstract: The successful development of the proteasome inhibitor bortezomib as an anticancer drug has improved survival in patients with multiple myeloma. With the emergence of the newly US Food and Drug Administration-approved proteasome inhibitor carfilzomib, ongoing trials are investigating this compound and other proteasome inhibitors either alone or in combination with other chemotherapy drugs. However, in solid tumors, the efficacy of proteasome inhibitors has not lived up to expectations. Results regarding the potential clinical efficacy of bortezomib combined with other agents in the treatment of solid tumors are eagerly awaited. Recent identification of the molecular mechanisms (involving apoptosis and autophagy) by which bortezomib and cisplatin can overcome chemotherapy resistance and sensitize tumor cells to anticancer therapy can provide insights into the development of novel therapeutic strategies for patients with solid malignancies.
authors.affiliation: Department of Obstetrics and Gynecology, Linkou Medical Center, Taoyuan, Taiwan.
authors.forename: Angel
authors.initials: A
authors.lastname: Chao
authors.affiliation: Department of Obstetrics and Gynecology, Linkou Medical Center, Taoyuan, Taiwan; Genomic Medicine Research Core Laboratory, Linkou Medical Center, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan; School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address: knoxtn@cgmh.org.tw.
authors.forename: Tzu-Hao
authors.initials: TH
authors.lastname: Wang
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001343:Autophagy / Q000187:drug effects; D000069286:Bortezomib / Q000008:administration & dosage / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D017671:Platinum Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D061988:Proteasome Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D017671:Platinum Compounds; D061988:Proteasome Inhibitors; D000069286:Bortezomib
keywords: apoptosis; autophagy; bortezomib; proteasome inhibitors; solid tumors